SL PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 141 million yuan, a year-on-year increase of 943.10%
According to the Zhitong Finance APP, SL PHARM released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 459 million yuan, a year-on-year decrease of 15.13%. The net profit attributable to shareholders of the listed company was 141 million yuan, a year-on-year increase of 943.10%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 29.3349 million yuan, a year-on-year decrease of 62.39%
According to the Zhitong Finance APP, SL PHARM (002038.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 459 million yuan, a year-on-year decrease of 15.13%. The net profit attributable to shareholders of the listed company was 141 million yuan, a year-on-year increase of 943.10%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 29.3349 million yuan, a year-on-year decrease of 62.39%
